Author:
Biedermann Monika,Zeyen Barbara
Publisher
Springer Berlin Heidelberg
Reference16 articles.
1. Belum VR, Marulanda K, Ensslin C, Gorcey L, Parikh T, Wu S, Busam KJ, Gerber PA, Lacouture ME (2015) Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 26(12):2496–2502. https://doi.org/10.1093/annonc/mdv390
2. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017 U.S. Department of Health and Human Services, National Cancer Institute. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Zugegriffen am 17.04.2022
3. Freites-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, Dusza S, Goldfarb S, Lacouture ME (2018) Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol 154(6):670. https://doi.org/10.1001/jamadermatol.2018.0454
4. Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, Lacouture ME (2019) Hair disorders in patients with cancer. J Am Acad Dermatol 80(5):1179–1196. https://doi.org/10.1016/j.jaad.2018.03.055
5. Gallicchio L, Calhoun C, Helzlsouer KJ (2013) Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat 142(2):435–443. https://doi.org/10.1007/s10549-013-2744-2